Harness this unique opportunity to accelerate the frontier of preventative and regenerative therapies to meaningfully target kidney disease and enlighten opportunities for indication expansion into rare renal disorders
In the war against renal diseases, leveraging novel strategies can be a game-changer and we know that the right insights and connections can sharpen the weapons that are in your arsenal.
We share a common belief with the industry – that the potential of improving therapeutics is enormous.
Your Next Meeting: March 1-3, 2022 | Boston
Join us at the 4th Chronic Kidney Disease Drug Development Summit to together discover opportunities to personalize organ-on-a-chip technology and explore advances in stem cell platforms to regenerate kidney tissue. Leave this meeting equipped to guide your strategic decisions for 2022 and implement evolving surrogate endpoints of eGFR slope, albuminuria, and real-world evidence into innovative trial design.
With over 150+ industry experts converging in Boston, including the FDA, AstraZeneca, Goldfinch Bio, Boehringer Ingelheim, Pfizer, Bayer, Sanofi, and more, don’t miss the pinnacle event in your Q1 calendar providing an unparalleled opportunity to network and secure partnerships for 2022 and beyond.
For more information about the upcoming meeting, visit: www.ckd3-summit.com